Halozyme slides on an early futility failure for its lead cancer therapy
Halozyme shares slipped 8% on Thursday after the biotech reported that one of its combo studies using PEGPH20 couldn’t clear an early test for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
